Self-testing has shifted the paradigm for HIV testing, the first step in the care continuum. Only 7 years ago, use of HIVST was limited due to lack of evidence of accuracy, acceptability, feasibility, and concerns about safety. Through Unitaid's initial catalytic investment in HIV Self-testing (HIVST) demand and supply interventions through the STAR and Atlas projects, followed by large donor investments including the Global Fund, CIFF, PEPFAR, BMGF, we are now witnessing large scale HIVST use around the world since WHO normative guidance for HIVST was released in 2016. Scale up of HIVST is also driving a movement towards differentiated service delivery and acceleration of prevention access, increasing health system resilience against COVID-19 and decreases cost and complexity of services. HIVST provided a foundation from which other self-testing and self-care approaches can now be more readily realized, including sexually transmitted infections, Hepatitis and COVID-19. In this session we will be reflecting on the levers that have contributed to the HIVST market growth and discussing how the evidence from supply and demand side interventions can be applied to self-care and self-testing approaches in other disease areas and present preliminary results from use cases for Covid-19 and Hepatitis C self-testing.

• Presentations
• Session recording (English)